Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
Identifieur interne : 004780 ( Main/Exploration ); précédent : 004779; suivant : 004781Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
Auteurs : Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2001-07.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Administration, Oral, Adrenergic alpha-Antagonists (adverse effects), Adrenergic alpha-Antagonists (therapeutic use), Aged, Antagonist, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Chemotherapy, Dose-Response Relationship, Drug, Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Female, Human, Humans, Idazoxan, Idazoxan (adverse effects), Idazoxan (therapeutic use), Levodopa (adverse effects), Levodopa (therapeutic use), L‐DOPA, dyskinesia, Male, Middle Aged, Neurologic Examination (drug effects), Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Phase II trial, Pilot Projects, Treatment, idazoxan, α2 receptors, α2-Adrenergic receptor.
- MESH :
- chemical , adverse effects : Adrenergic alpha-Antagonists, Antiparkinson Agents, Idazoxan, Levodopa.
- chemical , therapeutic use : Adrenergic alpha-Antagonists, Antiparkinson Agents, Idazoxan, Levodopa.
- drug effects : Neurologic Examination.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- Administration, Oral, Aged, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pilot Projects.
Abstract
Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induced dyskinesia. We assessed, in a pilot randomised placebo‐controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha‐2 antagonist, on motor parkinsonian disability and L‐DOPA‐induced dyskinesia following an acute oral challenge of L‐DOPA in 18 patients with Parkinson's disease. The severity of L‐DOPA‐induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L‐DOPA. These results suggest that blocking alpha‐2 receptors in patients with Parkinson's disease might improve L‐DOPA‐induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long‐term management of dyskinetic patients with Parkinson's disease. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/mds.1143
Affiliations:
- France
- Midi-Pyrénées, Île-de-France
- Paris, Toulouse
- Hôpital de la Salpêtrière, Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001B47
- to stream Istex, to step Curation: 001B47
- to stream Istex, to step Checkpoint: 003007
- to stream Main, to step Merge: 006C62
- to stream PascalFrancis, to step Corpus: 002966
- to stream PascalFrancis, to step Curation: 000355
- to stream PascalFrancis, to step Checkpoint: 002980
- to stream Main, to step Merge: 006E79
- to stream PubMed, to step Corpus: 003D03
- to stream PubMed, to step Curation: 003D03
- to stream PubMed, to step Checkpoint: 003D27
- to stream Ncbi, to step Merge: 000548
- to stream Ncbi, to step Curation: 000548
- to stream Ncbi, to step Checkpoint: 000548
- to stream Main, to step Merge: 006A29
- to stream Main, to step Curation: 004780
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name><affiliation><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I." last="Arnulf">I. Arnulf</name></author><author><name sortKey="Peyro Aint Paul, H" sort="Peyro Aint Paul, H" uniqKey="Peyro Aint Paul H" first="H." last="Peyro-Saint Paul">H. Peyro-Saint Paul</name></author><author><name sortKey="Brefel Ourbon, C" sort="Brefel Ourbon, C" uniqKey="Brefel Ourbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name></author><author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name></author><author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name></author><author><name sortKey="Descombes, S" sort="Descombes, S" uniqKey="Descombes S" first="S." last="Descombes">S. Descombes</name></author><author><name sortKey="Bejjani, B" sort="Bejjani, B" uniqKey="Bejjani B" first="B." last="Bejjani">B. Bejjani</name></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation><country>France</country><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D45B693FEB760DA50DF70021526CB4914873B8E7</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/mds.1143</idno><idno type="url">https://api.istex.fr/document/D45B693FEB760DA50DF70021526CB4914873B8E7/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001B47</idno><idno type="wicri:Area/Istex/Curation">001B47</idno><idno type="wicri:Area/Istex/Checkpoint">003007</idno><idno type="wicri:doubleKey">0885-3185:2001:Rascol O:idazoxan:an:alpha</idno><idno type="wicri:Area/Main/Merge">006C62</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:01-0429759</idno><idno type="wicri:Area/PascalFrancis/Corpus">002966</idno><idno type="wicri:Area/PascalFrancis/Curation">000355</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">002980</idno><idno type="wicri:doubleKey">0885-3185:2001:Rascol O:idazoxan:an:alpha</idno><idno type="wicri:Area/Main/Merge">006E79</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:11481696</idno><idno type="wicri:Area/PubMed/Corpus">003D03</idno><idno type="wicri:Area/PubMed/Curation">003D03</idno><idno type="wicri:Area/PubMed/Checkpoint">003D27</idno><idno type="wicri:Area/Ncbi/Merge">000548</idno><idno type="wicri:Area/Ncbi/Curation">000548</idno><idno type="wicri:Area/Ncbi/Checkpoint">000548</idno><idno type="wicri:doubleKey">0885-3185:2001:Rascol O:idazoxan:an:alpha</idno><idno type="wicri:Area/Main/Merge">006A29</idno><idno type="wicri:Area/Main/Curation">004780</idno><idno type="wicri:Area/Main/Exploration">004780</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease</title><author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I." last="Arnulf">I. Arnulf</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Peyro Aint Paul, H" sort="Peyro Aint Paul, H" uniqKey="Peyro Aint Paul H" first="H." last="Peyro-Saint Paul">H. Peyro-Saint Paul</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de recherche Pierre Fabre, Boulogne</wicri:regionArea><wicri:noRegion>Boulogne</wicri:noRegion><wicri:noRegion>Boulogne</wicri:noRegion></affiliation></author><author><name sortKey="Brefel Ourbon, C" sort="Brefel Ourbon, C" uniqKey="Brefel Ourbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Descombes, S" sort="Descombes, S" uniqKey="Descombes S" first="S." last="Descombes">S. Descombes</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Bejjani, B" sort="Bejjani, B" uniqKey="Bejjani B" first="B." last="Bejjani">B. Bejjani</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Neurology, Clinical Investigation Centre and INSERM U289, University Hospital of Pitie‐Salpetriere, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName><placeName><settlement type="city">Paris</settlement><region type="region" nuts="2">Île-de-France</region></placeName><orgName type="hospital" n="4">Hôpital de la Salpêtrière</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-07">2001-07</date><biblScope unit="vol">16</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="708">708</biblScope><biblScope unit="page" to="713">713</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">D45B693FEB760DA50DF70021526CB4914873B8E7</idno><idno type="DOI">10.1002/mds.1143</idno><idno type="ArticleID">MDS1143</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term><term>Adrenergic alpha-Antagonists (adverse effects)</term><term>Adrenergic alpha-Antagonists (therapeutic use)</term><term>Aged</term><term>Antagonist</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Chemotherapy</term><term>Dose-Response Relationship, Drug</term><term>Dyskinesia</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Female</term><term>Human</term><term>Humans</term><term>Idazoxan</term><term>Idazoxan (adverse effects)</term><term>Idazoxan (therapeutic use)</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>L‐DOPA, dyskinesia</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Phase II trial</term><term>Pilot Projects</term><term>Treatment</term><term>idazoxan</term><term>α2 receptors</term><term>α2-Adrenergic receptor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Adrenergic alpha-Antagonists</term><term>Antiparkinson Agents</term><term>Idazoxan</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic alpha-Antagonists</term><term>Antiparkinson Agents</term><term>Idazoxan</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Pilot Projects</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antagoniste</term><term>Chimiothérapie</term><term>Dyskinésie</term><term>Essai clinique phase II</term><term>Homme</term><term>Idazoxan</term><term>Parkinson maladie</term><term>Récepteur α2-adrénergique</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopatherapy. Preclinical data in the 1‐methyl‐4‐phenyl‐1,2,3,6,‐tetrahydropyridine (MPTP) monkey suggest that alpha‐2 antagonists may reduce dihydroxyphenylalanine (L‐DOPA)‐induced dyskinesia. We assessed, in a pilot randomised placebo‐controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha‐2 antagonist, on motor parkinsonian disability and L‐DOPA‐induced dyskinesia following an acute oral challenge of L‐DOPA in 18 patients with Parkinson's disease. The severity of L‐DOPA‐induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L‐DOPA. These results suggest that blocking alpha‐2 receptors in patients with Parkinson's disease might improve L‐DOPA‐induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long‐term management of dyskinetic patients with Parkinson's disease. © 2001 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>France</li></country><region><li>Midi-Pyrénées</li><li>Île-de-France</li></region><settlement><li>Paris</li><li>Toulouse</li></settlement><orgName><li>Hôpital de la Salpêtrière</li><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">Olivier Rascol</name></noRegion><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Yves Agid</name><name sortKey="Arnulf, I" sort="Arnulf, I" uniqKey="Arnulf I" first="I." last="Arnulf">I. Arnulf</name><name sortKey="Bejjani, B" sort="Bejjani, B" uniqKey="Bejjani B" first="B." last="Bejjani">B. Bejjani</name><name sortKey="Bonnet, A M" sort="Bonnet, A M" uniqKey="Bonnet A" first="A. M." last="Bonnet">A. M. Bonnet</name><name sortKey="Brefel Ourbon, C" sort="Brefel Ourbon, C" uniqKey="Brefel Ourbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name><name sortKey="Descombes, S" sort="Descombes, S" uniqKey="Descombes S" first="S." last="Descombes">S. Descombes</name><name sortKey="Fabre, N" sort="Fabre, N" uniqKey="Fabre N" first="N." last="Fabre">N. Fabre</name><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name><name sortKey="Peyro Aint Paul, H" sort="Peyro Aint Paul, H" uniqKey="Peyro Aint Paul H" first="H." last="Peyro-Saint Paul">H. Peyro-Saint Paul</name><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M." last="Vidailhet">M. Vidailhet</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004780 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 004780 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:D45B693FEB760DA50DF70021526CB4914873B8E7
|texte= Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |